EHA 2024 top abstracts: What’s hot in AML?

S130

14:45–15:00

The novel menin inhibitor ZE63-0302 has an impressive safety profile and unique chemistry that suggests improved efficacy against resistance mutations

Erin Hertlein

S131

15:00–15:15

Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: Topline efficacy and safety results from the pivotal AUGMENT-101 phase 2 study

Ibrahim Aldoss

S132

15:15–15:30

First-in-human phase 1/2 study of the menin-MLLinhibitor DSP-5336 in patients with relapsed or refractory acute leukemia: Updated results from dose escalation

Naval Daver

S133

15:30–15:45

A phase 1b study of the menin-KMT2A inhibitor JNJ-75276617 in combination with venetoclax and azacitidine in relapsed/refractory acute myeloid leukemia with alterations in KMT2A or NPM1

Andrew H. Wei

S134

15:45–16:00

Phase 1b study of azacitidine, venetoclax and revumenib in newly diagnosed older adults with NPM1mutated or KMT2A rearranged AML: Interim results of dose escalation from the Beat AML consortium

Joshua Zeidner

S135

11:30–11:45

Venetoclax-based salvage treatment for relapsed/refractory AML using a combination with high-dose cytarabine and mitoxantrone (HAM-VEN): Updated results of the phase-I/II SAL RELAX trial

Leo Ruhnke

S136

11:45–12:00

FLAG-IDA + venetoclax (VEN) in newly diagnosed (ND) or relapsed/refractory (RR) AML

Wei-Ying Jen

S138

12:15–12:30

Magrolimab vs placebo in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: The ENHANCE-3 study

Naval Daver

S139

12:30–12:45

Phase 1/2 study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia

Alex Bataller

S102

15:15–15:30

First results of the APOLLO trial: A randomized phase III study to compare ATO combined with ATRA versus standard AIDA regimen for patients with newly diagnosed, high-risk acute promyelocytic leukemia

Uwe Platzbecker

S141

16:45–17:00

A post hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes who received oral azacitidine maintenance therapy in the QUAZAR AML-001 study

Maria Teresa Voso

S142

17:00–17:15

QuANTUM-First: Efficacy in newly diagnosed patients with fms-like tyrosine kinase 3-internal tandem duplication–positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation therapy

Mikkael A. Sekeres

S144

17:30–17:45

Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort

Jorge Cortes

S265

16:30–16:45

Final long-term follow-up results of the RELAZA2 study: Azacitidine to treat measurable- residual disease in MDS and AML patients

Anne Sophie Kubasch

LB3444

11:00–11:15

Vitamin C supplementation in patients with clonal cytopenia of undetermined significance or low-risk myeloid malignancies: Results from EVI-2, a randomized, placebo-controlled phase 2 study

Stine Ulrik Mikkelsen

S146

11:45–12:00

Completed dose escalation from the first-in-human, phase 1/2 study of CD123 NK cell engager, SAR443579, in relapsed or refractory acute myeloid leukemia or high risk-myelodysplasia

Sylvain Garciaz

S148

12:15–12:30

Genomic landscape of adult AML with t(8;21)(q22;q22.1) and prognostic implications – results from the HARMONY platform

Alberto Hernandez-Sanchez

S149

12:30–12:45

Mini-consolidations versus intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A study from the DATAML and SAL registries

Christian Récher

P536

Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia study

Jorge Cortes

P540

Safety and activity of revumenib in combination with fludarabine/cytarabine (FLA) in patients with relapsed/refractory acute leukemias

Neerav Shukla

P560

Impact of TP53 mutations in patients with acute myeloid leukemia (AML) during oral azacitidine maintenance therapy: Outcomes from the QUAZAR AML-001 trial

Andrew H. Wei

P561

Gilteritinib plus venetoclax, low-dose cytarabine, and actinomycin D as first salvage therapy for relapsed or refractory FLT3 mutated acute myeloid leukemia

Andrius Žučenka

P565

FLAG regimen, combined with gemtuzumab (FLAG-GO) results in better optimal molecular response and outcomes, compared to combination with idarubicin (FLAG-IDA) in untreated core binding factor AML

Gautam Borthakur

P600

RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed/refractory AML and high-risk MDS: Preliminary results from two ongoing studies

Dominik Chraniuk

P603

Phase II study of cladribine, idarubicin, and higher dose cytarabine (CLIA) in patients with relapsed and/or refractory (R/R) acute myeloid leukemia (AML)

Tapan Kadia

P623

Reduced dose FLAG-mitoxantrone and low dose venetoclax induces deep remissions and high rate of transition to successful allogeneic stem cell transplantation in relapsed/refractory AML

Ahmad Ibrahim

P571

Real-world use of oral-azacitidine as maintenance therapy for acute myeloid leukemia in remission: Characteristics and outcomes of a French patient population

Christian Récher

P573

Prognostic relevance of TP53 mutations with or without concomitant complex karyotype in patients treated with CPX-351: Evidence from a large real-world Italian study.

Elisabetta Todisco

P1377

Long term efficacy results of the SIERRA trial: A phase 3 study of 131I-apamistamab-led allogeneic hematopoietic cell transplantation versus conventional care in older patients with active, R/R AML

James M Foran

P1786

Pregnancy outcomes in patients with acute leukemia diagnosed at different gestation ages: A more than 30 years national research group for the treatment of acute leukemia experience

Vera Troitskaya

P1792

Time to hematologic recovery is a critical determinant of complete remission as a surrogate for overall survival after intensive chemotherapy for acute myeloid leukemia

Rithin Nedumannil

P1805

Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia in Canada

Brian Leber

P1810

Real-world use of first-line midostaurin in FLT3-mutated acute myeloid leukemia: A multicentric study from the Grupo Português de Leucemias Agudas

Joana Infante

P1818

The role of allo-HSCT in AML CR1 patients with MRD negativity after the first induction course

Elena Parovichnikova